A new study reveals that the presence of certain bacteria in the gut may significantly influence an individual’s response to a widely used class of antidepressants. Researchers found that these microbial communities could either enhance or reduce the effectiveness of medications commonly prescribed for depression, suggesting a potential link between gut health and mental health treatment outcomes. The findings highlight how personalized approaches to medication—considering a patient’s microbiome—might improve therapeutic success. Experts caution that further investigation is needed before clinical recommendations can be made.